Victoria Socha

DocwireNews

American Society of Transplant Surgeons Winter SymposiumAmong recipients of deceased donor kidney transplants, approximately 31% are affected by delayed graft function; in 2% of those cases, delayed graft function remains unsolved beyond 2 weeks. Biomarkers that predict the time to resolution of delayed graft function would allow optimal immunosuppression levels in the period immediately post-transplant.Noninvasive assessment of kidney <a href="https://www.docwirenews.com/docwire-pick/monitoring-allograft-rejection-with-dd-cfdna-testing/">allograft</a> injury and rejection can be achieved via measurement of donor-derived cell-free DNA (dd-cfDNA). Patients with dd-cfDNA levels elevated &ge;1% are at risk for kidney rejection.There are few data on the ability of dd-cfDNA to predict resolution in delayed graft function. Obi Davies-Ekwenna, MD, of the University of Toledo Medical Center, Toledo, Ohio, and colleagues conducted a retrospective analysis of data on 16 patients who underwent deceased-donor kidney transplantation and subsequently developed delayed graft function. Results of the analysis were <a href="https://asts.org/events-meetings/winter-symposium#.YEjRn11Kiko">reported</a> during a virtual poster session at the American Society of Transplant Surgeons 21st Annual State of the Art Winter Symposium in a poster titled Elevated Donor-Derived Cell-Free DNA in Patients with Delayed Graft Function.At an average of 2 weeks post-transplant, Prospera,&trade; a clinically validated dd-cfDNA assay was used to detect active rejection in each patient. At 4 to 9 weeks post-transplant, 13 of the 16 patients had one or more follow-up blood draws. Seven of the 16 had a biopsy accompanying one of the dd-cfDNA tests.Mean dd-cfDNA level at the first blood draw was 1.32% (range 0.03% to 4.98%). Average time from transplant to first test was 15.57 days (range 5 to 28 days). Seven of the 16 patients had for-cause biopsies, and two had rejection. Both patients who had rejection had initial dd-cfDNA readings &ge;1% threshold.At the time of the first blood draw, nine patients had elevated dd-cfDNA levels (&ge;1%). Six of seven patients whose dd-cfDNA levels were &lt;1% had resolution of delayed graft function within 2 weeks. Of the nine patients with elevated dd-cfDNA levels, six had resolution of delayed graft function within 2 weeks. One patient who had consistently elevated dd-cfDNA levels had persistent delayed graft function. At the follow-up blood draw, there was a mean decline of 30% in dd-cfDNA levels among those with elevated levels at the first draw.&ldquo;in this cohort, dd-cfDNA readings &lt;1% were consistent with resolution of delayed graft function. Persistently elevated dd-cfDNA levels were associated with delayed graft function. Serial dd-cfDNA testing can be beneficial in monitoring kidney transplant patients with delayed graft function,&rdquo; the researchers said.Source: Davies-Ekwenna O, Brown ML, McCormick S, et al. Elevated donor-derived cell-free DNA in patients with delayed graft function. Poster presented at the American Society of Transplant Surgeons virtual 21st Annual State of the Art Winter Symposium (E-poster 50), January 14, 2021. Support for this study was provided by Natera, Inc.

Brandon Twyford

DESTINY-Breast09 Demonstrates First-Line Superiority of Enhertu Plus Pertuzumab in HER2-Positive Metastatic Breast Cancer

HER2 Breast Cancer

Trodelvy Plus Keytruda Significantly Improves Progression-Free Survival in PD-L1+ mTNBC, Phase III Data Show

Triple-Negative Breast Cancer

Jordana Jampel

Actress Michelle Trachtenberg's Premature Death From Diabetes Reveals Dangers of Chronic Complications

Diabetes

Latest News

Elevated dd-cfDNA Levels to Monitor Patients with Delayed Graft Function

Kidney Transplantation

American Society of Transplant Surgeons Winter Symposium ...

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Metabolic Acidosis

Nephrology Times

HR Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe